E-Science Station

Metabolic syndrome (MetS) is widely discussed lately. It consists of hypertension, abdominal obesity, dyslipidemia, insulin resistance and considered risk for the development of the cardiovascular disease and type 2 diabetes mellitus. We aimed to estimate the effect of MetS on mid-term outcomes after percutaneous intervention (PCI) with drug-eluting stents.

We have investigated 132 patients with MetS (male=61;mean age 61.4 years) compared to those of 52 patients without MetS (male=27;mean age 61.8 years old) in the interventional cardiology department of the Republican specialized scientific-practical medical center of therapy and medical rehabilitation. Metabolic syndrome was defined by the “Harmonized definition of the MetS”. The medium follow-up period was 5.5 years. A composite event consisted of repeat revascularization, unstable angina, non-fat almyocardial infarction and cardiac death.

Patients who had metabolic syndrome were associated with a significant restenosis (odd ratio (OR) 1.34, Confidential Interval (CI) 95%, 0.95-1.84) and adverse cardiac events (OR 1.38; CI 95%,0.95-1.91) than those of patients without of this syndrome (restenosis: OR1.12; CI 95%, 0.92-1.51; adverse cardiac events (OR 1.15; CI 95%, 0.95-1.60; p<0.05)in medium follow-up. Furthermore, MetS components showed a significant relationship to the composite events. When compared with control group, the adjusted hazard ratio for one, two or three and more MetS components was associated with hazard ratio respectively 1.38 (95% CI: 0.89–1.82); 1.82 (95% CI:1.24–2.82); 2.12 (95% CI: 1.39-2.56). Cox regression analysis showed that MetS as a significant predictor of major adverse cardiovascular events in patients whom undergone percutaneous interventions with DES.

Metabolic syndrome increases composite event risks inpatients who underwent PCI with DES. The risk is worse with increasing number of MetS components. Further studies are needed to clarify with large amount of patients.